Recent studies, however, have suggested that, in contrast to ESO-specific CD4+ T cells primed through vaccination, ESO-specific CD4+ T cells in patients with spontaneous immune responses may contain significant proportions of Treg [19] and that elevated proportions of circulating Treg in cancer patients may impair their responsiveness to ESO vaccines [20]. Here, CD4 is linked to cancer.